Study Evaluating AGG-523 in Subjects With Osteoarthritis
Phase 1
Completed
- Conditions
- Osteoarthritis
- Registration Number
- NCT00427687
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Brief Summary
This study will evaluate the effect of AGG-523 administration on biomarkers related to osteoarthritis. Safety and tolerability of AGG-523 will also be assessed.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method The effect of AGG-523 on biomarkers related to osteoarthritis.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms of AGG-523 (celecoxib + chondroitin sulfate) affect synovial inflammation and cartilage matrix in osteoarthritis?
How does AGG-523's efficacy in mild to moderate OA compare to standard-of-care NSAIDs like celecoxib monotherapy?
Which biomarkers in NCT00427687 correlate with AGG-523's pharmacodynamic effects on cartilage degradation in OA patients?
What adverse events were observed in AGG-523's Phase 1 OA trial and how are they managed compared to other COX-2 inhibitors?
What pharmacokinetic interactions exist between AGG-523 components and how do they influence OA treatment strategies?